SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Walt Disney Co. is trending as community members react to news of Jimmy Kimmel's show returning, sparking debates about free speech, censorship, and the company's direction. Some investors express concerns about Disney potentially alienating portions of its audience, while others see a buying opportunity amidst the controversy. The stock's long-term potential is also being weighed against immediate market reactions within the context of the broader streaming landscape.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as rumors of a hyperscaler deal, possibly with Oracle, gain traction within investor communities. The community is actively discussing the potential for significant returns driven by the company's pivot towards High-Performance Computing (HPC) and AI data centers, drawing comparisons to sector peers.  Enthusiasm is further fueled by anticipation of upcoming news and confidence in the company's strategic direction within the burgeoning AI infrastructure landscape.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending amid high short interest and borrow fees, sparking discussions of a potential short squeeze. Community members are debating whether a large shareholder will trigger a squeeze, while others highlight the stock's volatility and potential for both significant gains and losses. The stock's connection to a well-known investor and its standing on short squeeze leaderboards are also driving interest.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as the community speculates on a potential hyperscaler deal and its ties to Nvidia's AI initiatives, driving significant price movement. Talk centers around potential partnerships and anticipation of substantial upside due to secured contracts amid growing AI infrastructure demand. Some traders are also highlighting potential short squeeze opportunities.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as the community debates whether it represents a value opportunity or a value trap, with some citing its low P/E ratio and high dividend yield. Discussions include TRC Capital's mini-tender offer and speculation about potential catalysts like Taylor Swift's new album, while others express concern over falling sales and overall market performance.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance Holding Co. is trending as community members discuss a potential pump and dump scheme following comments from a hedge fund manager comparing it to Shopify, with a potential upside of "350x in 2 years".  The conversation includes both bullish and bearish sentiment, with some drawing comparisons to hedge fund manager Eric Jackson's previous promotion of Opendoor. Community members are also actively analyzing warrant pricing and the potential for a short squeeze due to the low float.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following news of its acquisition of Paige, a leader in digital pathology, aimed at enhancing AI-powered cancer diagnostics. Community discussions revolve around the potential impact of this acquisition on Tempus's market position and its broader strategy in the AI healthcare space.  However, some are expressing concern over insider selling and the valuation of the stock.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors discuss the potential impact of strategic partnerships and upcoming catalysts, including key launches. Community members are focused on the company's long-term potential in providing satellite connectivity, referencing previous highs and expressing optimism about future growth. Discussions also include speculation around government contracts and spectrum rights.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace ($FLY) is trending following its IPO, with the community actively debating its valuation and future prospects after the initial excitement. Mixed opinions on the company's growth potential and execution risks are fueling discussions, with some comparing it to competitors while others express concern over profitability. The stock's volatile price action is contributing to the heightened interest and varied perspectives.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending as investors debate its future growth potential and fair valuation, with some expressing frustration over its recent performance compared to other tech giants. A mixed sentiment prevails, with some expecting a breakout to new all-time highs while others foresee a potential drop, sparking active discussions about entry points and trading strategies. Discussions have also been focused around a recent judge ruling that Amazon violated online shopper protection laws in Prime billing case.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Stock Index Futures Slip as Tariff-Driven Selloff Continues, U.S. Jobs Report and Powell Speech in Focus

June S&P 500 E-Mini futures (ESM25) are down -0.84%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.52% this morning, pointing to a continued selloff on Wall Street following U.S. President Donald Trump’s announcement of sweeping tariffs, while investors await the key U.S. payrolls report and remarks from Federal Reserve Chair Jerome Powell.

Shares of Eli Lilly &amp; Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by fears of a global economic fallout from President Donald Trump’s reciprocal tariff blitz.However, retail investors took heart in the fact that the pharmaceutical industry suffered a relatively lighter blow compared to sectors like technology and manufacturing, as it was largely spared from the government’s targeted tariff list.On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’<figure class="image"><img style="aspect-ratio:1314/320;" src="https://news.stocktwits-cdn.com/LLY_sentiment_and_message_volume_on_April_3_png_0331ef626f.webp" alt="LLY sentiment and message volume on April 3.png" width="1314" height="320"><figcaption>LLY sentiment and message volume on April 3. | source: Stocktwits</figcaption></figure>“LLY isn’t even affected. Loading up on calls at the open!” one user posted early Thursday when the stock was still in the green.<stembedurl>https://stocktwits.com/DayTrader6969/message/610222644</stembedurl>Another user pointed out that Trump had specifically highlighted Lilly as a company investing in U.S. infrastructure and job creation, suggesting it could ultimately benefit from the administration’s policies.<stembedurl>https://stocktwits.com/MrChoudhury/message/610228354</stembedurl>Back in February, when Trump threatened to impose tariffs on drug imports, Lilly unveiled a plan to invest $27 billion on new plants in the United States over the next five years.However, as drugmakers dig through the fine print of Trump's sweeping executive order — which imposes a 10% baseline duty on most imports — uncertainty remains over whether the pharmaceutical industry will be completely spared.Media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/pharma-stocks-up-on-us-tariff-exemptions-but-analyst-flags-a-46b-import-cost-risk-3964936">reports</a> suggest a U.S. official hinted that a separate round of tariffs targeting pharmaceuticals is still on the table.According to Bernstein analysts, if country-specific tariffs are applied, the pharmaceutical industry could face up to $46 billion in additional import costs.For now, investors seem to be taking a small win in stride.Retail traders on Thursday also zeroed in on Lilly’s newly inked licensing deal with Sangamo Therapeutics for its adeno-associated virus capsid,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgmo-stock-falls-after-q4-2024-earnings-miss/ch7KGZ9Rbca">STAC-BBB</a>, designed to improve the delivery of IV-administered genomic medicines for neurological diseases.The deal grants Lilly exclusive global rights to use STAC-BBB for one initial central nervous system target, with the option to expand to four more for additional fees.Lilly's stock has gained a little over 1% this year, while the Dow Jones U.S. Health Care Index is up over 2.5% and the S&amp;P 500 Health Care Index has risen over 4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption

On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 

Equity

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMO Sangamo Therapeutics Inc